Report of Foreign Issuer (6-k)
2019年8月15日 - 3:53AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C.
20549
FORM 6-K
REPORT OF FOREIGN
PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES
EXCHANGE ACT OF 1934
For the month of
August 2019
Commission File Number: 001-38764
Aptorum Group Limited
17
th
Floor, Guangdong Investment
Tower
148 Connaught Road Central
Hong Kong
(Address of principal executive office)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Entry into Line of Credit Agreements
and Promissory Notes.
On August 13, 2019
(the “Effective Date”), Aptorum Therapeutics Limited (“ATL”), wholly-owned subsidiary of Aptorum
Group Limited, entered into two separate Promissory Notes and Line of Credit Agreements (the “Agreements”) with Aeneas
Group Limited (“Aeneas Group”) and Jurchen Investment Corporation (“Jurchen”). The Aeneas Group Agreement
and Jurchen Agreement provide ATL with a line of credit up to twelve million dollars ($12,000,000) and three million dollars
($3,000,000), respectively (collectively, the “Line of Credit”), representing the maximum aggregate amount of the advances
of funds from the Line of Credit that may be outstanding at any time under the Line of Credit (the “Principal Indebtedness”).
ATL may draw down from the Line of Credit at any time through the day immediately preceding the third anniversary of the
Effective Date (the “Maturity Date”). Interest will be payable on the outstanding Principal Indebtedness at the rate
of eight percent (8%) per annum, payable semi-annually in arrears on February 12 and August 12 in each year. ATL may pre-pay
in whole or in part, the Principal Indebtedness of the Line of Credit, and all interest accrued at any time prior to the Maturity
Date, without penalty. Under the Agreements, in addition to certain standard covenants, we are also not permitted, without the
prior written consent of Aeneas Group and Jurchen to (i) liquidate, dissolve or wind-up our business and affairs; (ii) effect any
merger or consolidation transaction; (iii) sell, lease, transfer, license or otherwise dispose, in a single transaction or series
of related transactions, all or substantially all of our assets; or (iv) consent to any of the foregoing. The Agreements are subject
to standard events of default, which if not cured within the agreed upon cure period, permits Aeneas Group or Jurchen, as applicable,
to declare the outstanding Principal Indebtedness immediately due and payable, to exercise any other remedy provided for in the
Agreements or any other right available to Aeneas Group or Jurchen as provided at law or in equity. Jurchen and Aeanas Group also
maintain the right to set-off during the term of the Agreements.
Both Aeneas Group
and Jurchen are related parties. Aeneas Group is a wholly-owned subsidiary of Aeneas Limited, an entity 80% owned by Jurchen. Jurchen
is a company wholly-owned by Mr. Huen, and a controlling shareholder of Aptorum Group Limited.
Copies of the forms
of the Agreements are attached hereto as Exhibit 10.1 and 10.2, respectively.
Exhibits
See the Exhibit Index
hereto.
EXHIBIT INDEX
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
Date: August 14, 2019
|
Aptorum Group Limited
|
|
|
|
|
By:
|
/s/ Sabrina Khan
|
|
|
Sabrina Khan
|
|
|
Chief Financial Officer
|
Aptorum (NASDAQ:APM)
過去 株価チャート
から 3 2024 まで 4 2024
Aptorum (NASDAQ:APM)
過去 株価チャート
から 4 2023 まで 4 2024